Jazz Pharmaceuticals

Last updated
Jazz Pharmaceuticals plc
Company type Public
Industry
PredecessorJazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland)
Founded2003;21 years ago (2003) in California, U.S.
Headquarters Dublin, Ireland
Area served
Worldwide
Key people
Bruce C. Cozadd (chairman and CEO)
Products Pharmaceutical drugs
Brands
RevenueIncrease2.svg US$3.83 billion (2023)
Increase2.svgUS$579 million (2023)
Increase2.svgUS$415 million (2023)
Total assets Increase2.svgUS$11.4 billion (2023)
Total equity Increase2.svgUS$3.74 billion (2023)
Number of employees
c. 2,800 (2023)
Website jazzpharma.com
Footnotes /references
[1]

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. [2] One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. [1] In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. [3]

Contents

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. [4]

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). [5]

Company history and acquisitions

2010–2019

On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. [6] In the following December, a new patent was issued for Sodium Oxybate. [7]

On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia. [8] [9]

On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). [10] In September, the company sold its Women's Health business to Meda for $95 million. [11] In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia. [12]

In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion. [13] [14]

In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. [15] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion. [16] As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia. [17]

In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million. [18] [19]

2020–present

In January 2021, Jazz announced it would acquire GW Pharmaceuticals for US$7.2 billion at $220 per ADR - $200.00 in cash and $20.00 in shares of Jazz. [20] [21] Jazz Pharmaceuticals acquired GW Pharmaceuticals's cannabis business in the acquisition. [22]

Acquisition history

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Sodium oxybate</span> Medication to treat symptoms of narcolepsy

Sodium oxybate, sold under the brand name Xyrem among others, is a medication used to treat symptoms of narcolepsy: sudden muscle weakness and excessive daytime sleepiness. It is used sometimes in France and Italy as an anesthetic given intravenously; it is also approved and used in Italy and in Austria to treat alcohol dependence and alcohol withdrawal syndrome.

<span class="mw-page-title-main">Otsuka Pharmaceutical</span> Japanese pharmaceutical company

Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd..

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American-headquartered life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

Xywav is a medication used to treat cataplexy or excessive daytime sleepiness. It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate. It is a central nervous system (CNS) depressant and it is taken by mouth.

References

  1. 1 2 "Jazz Pharmaceuticals PLC 2023 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. 28 February 2024. Retrieved 28 February 2024.
  2. ↑ "History". Jazz Pharmaceuticals. Archived from the original on 23 November 2016. Retrieved 22 November 2016.
  3. ↑ "Axsome To Buy Sunosi From Jazz". NASDAQ . Retrieved 28 March 2022.
  4. ↑ "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation". Archived from the original on 2021-07-20. Retrieved 2016-06-08.
  5. ↑ "Teva wins controversial PhRMA bid despite protests from branded rivals". 18 July 2016. Archived from the original on 19 July 2016. Retrieved 18 July 2016.
  6. ↑ "FDA accepts NDA for JZP-6, a treatment for fibromyalgia". empr.com. 2010-02-19.
  7. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  8. ↑ "Jazz Pharmaceuticals Inc and Azur Pharma to combine". manufacturingchemist.com. 2011-09-20.
  9. ↑ Hancock, Ciaran (2011-09-21). "Azur to merge with US pharma firm in $500m deal". manufacturingchemist.com.
  10. ↑ Armstrong, Mike (2012-04-27). "Jazz Pharmaceuticals to buy Langhorne's Eusa". The Philadelphia Inquirer. Retrieved 2022-05-20.
  11. ↑ "Meda buys women's health unit of Jazz Pharma". pharmatimes.com. 2012-09-07. Retrieved 2022-05-20.
  12. ↑ "Jazz Initiates Erwinaze Trial - Zacks Equity Research". yahoo.com. 2012-12-05. Retrieved 2022-05-20.
  13. ↑ Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News. Archived from the original on 2015-01-12. Retrieved 2017-03-08.
  14. ↑ "Jazz Pharma Acquiring Gentium for $1B" (paper). Gen. Eng. Biotechnol. News . 34 (2): 10. January 15, 2014.
  15. ↑ "Alizé Pharma II Acquired by Jazz Pharmaceuticals for Up to $20.5M - GEN News Highlights - GEN".
  16. ↑ "Jazz Pharmaceuticals to Acquire Celator for $1.5B - GEN News Highlights - GEN". 31 May 2016. Archived from the original on 1 June 2016. Retrieved 31 May 2016.
  17. ↑ "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Archived from the original on 2019-04-11. Retrieved 2018-12-30.
  18. ↑ "Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc". Archived from the original on 2022-03-05. Retrieved 2019-08-18.
  19. ↑ "Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc. | Jazz Pharmaceuticals PLC". Archived from the original on 2019-08-18. Retrieved 2019-08-18.
  20. ↑ "Jazz Pharmaceuticals to Acquire GW Pharmaceuticals PLC, Creating an Innovative, High-Growth, Global Biopharma Leader". Archived from the original on 2022-03-05. Retrieved 2021-02-03.
  21. ↑ "Jazz Pharma to buy GW Pharma for $7.2 billion, adding cannabis-based drug to portfolio". Reuters. 3 February 2021. Archived from the original on 3 February 2021. Retrieved 3 February 2021.
  22. ↑ https://www.fiercepharma.com/pharma/jazz-and-gw-pharma-grow-cannabinoid-manufacturing-ambitions-new-100m-plant
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.